AE-941 (Neovastat) versus placebo in metastatic renal cell carcinoma patients who are refractory to immunotherapy

Trial Profile

AE-941 (Neovastat) versus placebo in metastatic renal cell carcinoma patients who are refractory to immunotherapy

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Mar 2013

At a glance

  • Drugs AE 941 (Primary)
  • Indications Renal cell carcinoma
  • Focus Registrational; Therapeutic Use
  • Sponsors AEterna Zentaris Inc
  • Most Recent Events

    • 07 Feb 2008 Status changed from in progres to completed.
    • 27 Dec 2007 New trial record.
    • 24 Sep 2003 Primary endpoint 'Survival' has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top